Ikaros family zinc finger 1 mutation is a poor prognostic factor for adult Philadelphia chromosome positive acute lymphoblastic leukemia
10.3760/cma.j.issn.0578-1426.2019.04.012
- VernacularTitle:Ikaros家族锌指蛋白1基因突变是成人费城染色体阳性急性淋巴细胞白血病预后不良因素
- Author:
Shanhao TANG
1
;
Ying LU
;
Pisheng ZHANG
;
Xuhui LIU
;
Xiaohong DU
;
Dong CHEN
;
Shuangyue LI
;
Junjie CAO
;
Lieguang CHEN
;
Jing LE
;
Suying QIAN
;
Yongwei HONG
;
Renzhi PEI
Author Information
1. 宁波市鄞州人民医院血液科 315040
- Keywords:
Philadelphia chromosome;
Acute lymphoblastic leukemia;
Prognosis;
Ikaros family zinc finger 1 gene
- From:
Chinese Journal of Internal Medicine
2019;58(4):301-306
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the prognostic impact of Ikaros family zinc finger 1(IKZF1)mutation on adult Philadelphia chromosome (Ph1) positive acute lymphoblastic leukemia (ALL) patients.Methods IKZF1 mutation was detected in 63 adult Phi positive ALL patients at diagnosis using capillary electrophoresis.Recruited patients were treated in our center and other three hospitals in Ningbo from January 2014 to January 2017.Clinical data were collected and retrospectively analyzed.Results Thirty-nine (61.9％) patients were positive IKZF1 mutation in this cohort.The white blood cell (WBC) count in IKZF1 mutation group was significantly higher than that of mutation negative group [(64.6±11.3)× 109/L vs.(33.7±5.6)×109/L,P＜0.05].Patients with WBC count over 30×109/L accounted for 56.4％ in IKZF1 mutation group.Complete remission (CR) rate in the IKZF1 mutation group was also lower than that of negative group after induction chemotherapy (64.1％ vs.75.0％,P＞0.05).IKZF1 was a negative prognostic factor but not independent factor for survival by univariate and multivariate analyses.Patients were divided into chemotherapy and allogeneic transplantation groups.The 3-year overall survival (OS) rate and 3-year leukemia-free survival (LFS) rate in IKZF1 mutation group were significantly lower than those of negative group in both transplantation group (42.3％ vs.59.3％;31.2％ vs.50.0％;respectively,both P＜0.05) and chemotherapy group (24.8％ vs.40.0％;19.0％ vs.34.3％;respectively,both P＜0.05).Conclusion IKZF1 mutation is a poor prognostic factor for adult Ph1 positive ALL patients.
